Mrs Brenda Shanahan
Mrs Shanahan is an established member of the Australian finance community who has also spent more than two decades working and investing in medical R&D and commercialisation. She is currently a non-executive director of DMP Asset Management, Bell Financial Group (ASX: BFG, since 2012) and Phoslock Ltd (ASX: PHK, since 2017), as well as a director of the Kimberly Foundation of Australia Ltd and Chair of the Aikenhead Centre for Medical Discovery in Melbourne.
Previously Mrs Shanahan was a member of the Australian Stock Exchange, an executive director of a stockbroking firm, a fund management company and an actuarial company, and chair of the St Vincent’s Medical Research Institute. She was also Chair of Challenger Listed Investments Ltd, the reporting entity for four ASX listed firms (CKT, CIF, CDI and CWT) and a non-executive director of Challenger Limited (ASX: CGF).
Mrs Shanahan joined CLINUVEL in 2007, and was Non-Executive Chair of the Board from late 2007 until July 2010. Her depth of experience across global markets and medical research provides significant value to the current Board and Company.